The DOI matches its Crossref record; 346 of the 346 references it cites were found in a registry or an index.
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
Open accessAbstract
Sodium-glucose co-transporter 2 (SGLT2) inhibitors block glucose reabsorption in the renal proximal tubule, an insulin-independent mechanism that plays a critical role in glycemic regulation in diabetes. In addition to their glucose-lowering effects, SGLT2 inhibitors prevent both renal damage and the onset of chronic kidney disease and cardiovascular events, in particular heart failure with both reduced and preserved ejection fraction. These unexpected benefits prompted changes in treatment guidelines and scientific interest in the underlying mechanisms. Aside from the target effects of SGLT2 inhibition, a wide spectrum of beneficial actions is described for the kidney and the heart, even though the cardiac tissue does not express SGLT2 channels. Correction of cardiorenal risk factors, metabolic adjustments ameliorating myocardial substrate utilization, and optimization of ventricular loading conditions through effects on diuresis, natriuresis, and vascular function appear to be the main underlying mechanisms for the observed cardiorenal protection. Additional clinical advantages associated with using SGLT2 inhibitors are antifibrotic effects due to correction of inflammation and oxidative stress, modulation of mitochondrial function, and autophagy. Much research is required to understand the numerous and complex pathways involved in SGLT2 inhibition. This review summarizes the current known mechanisms of SGLT2-mediated cardiorenal protection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Inflammation and metabolic disorders
Hotamisligil, G. S. (2006) · Nature · doi:10.1038/nature05485 · Cited by 9,199
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Cardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Empagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845 · cited 2×
“Hospitalization for heart failure reduction rather than prevention of atherothrombotic events was, therefore, considered the major benefit associated with the use of gliflozins in CV patients [94].”
BackgroundObesity and Kidney Disease: Hidden Consequences of the Epidemic
Kovesdy, C. P., Furth, S. L., Zoccali, C., & on behalf of the World Kidney Day Steering Committee (2017) · American Journal of Nephrology · doi:10.1159/000458467 · Cited by 2,217
The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease
Youm, Y.-H., Nguyen, K. Y., Grant, R. W., Goldberg, E. L., Bodogai, M., Kim, D., D'Agostino, D., Planavsky, N., Lupfer, C., Kanneganti, T. D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3804 · Cited by 2,172
Sotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868
Suppression of Oxidative Stress by β-Hydroxybutyrate, an Endogenous Histone Deacetylase Inhibitor
Shimazu, T., Hirschey, M. D., Newman, J., He, W., Shirakawa, K., Le Moan, N., Grueter, C. A., Lim, H., Saunders, L. R., Stevens, R. D., et al. (2013) · Science · doi:10.1126/science.1227166 · Cited by 1,777
Cardiovascular outcomes with ertugliflozin in type 2 diabetes
Cannon, C. P., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Masiukiewicz, U., Charbonnel, B., Frederich, R., Gallo, S., Cosentino, F., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004967 · Cited by 1,514
Biology of Human Sodium Glucose Transporters
Wright, E. M., Loo, D. D. F., & Hirayama, B. A. (2011) · Physiological Reviews · doi:10.1152/physrev.00055.2009 · Cited by 1,430
Molecular mechanisms and physiological functions of mitophagy
Onishi, M., Yamano, K., Sato, M., Matsuda, N., & Okamoto, K. (2021) · The EMBO Journal · doi:10.15252/embj.2020104705 · Cited by 1,416
Body Mass Index and Risk for End-Stage Renal Disease
Hsu, C.-Y., McCulloch, C. E., Iribarren, C., Darbinian, J., & Go, A. S. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-1-200601030-00006 · Cited by 1,390
Heerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376
Cherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329
Sotagliflozin in patients with diabetes and chronic kidney disease
Bhatt, D. L., Szarek, M., Pitt, B., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Inzucchi, S. E., Kosiborod, M. N., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030186 · Cited by 1,205
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134
Podocyte loss and progressive glomerular injury in type II diabetes.
Pagtalunan, M. E., Miller, P. L., Jumping-Eagle, S., Nelson, R. G., Myers, B. D., Rennke, H. G., Coplon, N. S., Sun, L., & Meyer, T. W. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119163 · Cited by 1,088
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Verma, S., & McMurray, J. J. V. (2018) · Diabetologia · doi:10.1007/s00125-018-4670-7 · Cited by 999
Inhibiting Mitochondrial Fission Protects the Heart Against Ischemia/Reperfusion Injury
Ong, S.-B., Subrayan, S., Lim, S. Y., Yellon, D. M., Davidson, S. M., & Hausenloy, D. J. (2010) · Circulation · doi:10.1161/circulationaha.109.906610 · Cited by 986
CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
Ferrannini, E., Mark, M., & Mayoux, E. (2016) · Diabetes Care · doi:10.2337/dc16-0330 · Cited by 975
Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment
Tonneijck, L., Muskiet, M. H. A., Smits, M. M., van Bommel, E. J., Heerspink, H. J. L., van Raalte, D. H., & Joles, J. A. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016060666 · Cited by 887 · cited 1×
“An absolute and supraphysiologic elevation in the glomerular filtration rate (GFR) is observed early in the natural history of 10–67% and 6–73% of T1DM and T2DM patients, respectively [80].”
Background10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s010 · Cited by 869
Bolinder, J., Ljunggren, Ö., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A. M., Sugg, J., & Parikh, S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2260 · Cited by 867
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
Lambers Heerspink, H. J., de Zeeuw, D., Wie, L., Leslie, B., & List, J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12127 · Cited by 837
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70704 · Cited by 795
Mitochondrial Fission Inhibitors Suppress Endothelin-1-Induced Artery Constriction
Chen, C., Gao, J.-L., Liu, M.-Y., Li, S.-L., Xuan, X.-C., Zhang, X.-Z., Zhang, X.-Y., Wei, Y.-Y., Zhen, C.-L., Jin, J., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479536 · Cited by 782
Inzucchi, S. E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, M., Schmoor, C., Ohneberg, K., Johansen, O. E., George, J. T., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1096 · Cited by 740
Ferrannini, E., Baldi, S., Frascerra, S., Astiarraga, B., Heise, T., Bizzotto, R., Mari, A., Pieber, T. R., & Muscelli, E. (2016) · Diabetes · doi:10.2337/db15-1356 · Cited by 712
The Failing Heart Relies on Ketone Bodies as a Fuel
Aubert, G., Martin, O. J., Horton, J. L., Lai, L., Vega, R. B., Leone, T. C., Koves, T., Gardell, S. J., Krüger, M., Hoppel, C. L., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.017355 · Cited by 707
The Global Epidemiology of Diabetes and Kidney Disease
Koye, D. N., Magliano, D. J., Nelson, R. G., & Pavkov, M. E. (2018) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2017.10.011 · Cited by 686
Bonner, C., Kerr-Conte, J., Gmyr, V., Queniat, G., Moerman, E., Thévenet, J., Beaucamps, C., Delalleau, N., Popescu, I., Malaisse, W. J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3828 · Cited by 670 · cited 4×
“Some authors observe that SGLT-Is, through direct and indirect effects, stimulate lipolysis, liver ketogenesis, and an insulin production reduction, thus increasing ketone storage and ketonemia, and consequently the risk of DKA [43].”
BackgroundInfluentialBaartscheer, A., Schumacher, C. A., Wüst, R. C. I., Fiolet, J. W. T., Stienen, G. J. M., Coronel, R., & Zuurbier, C. J. (2017) · Diabetologia · doi:10.1007/s00125-016-4134-x · Cited by 661
Santos-Gallego, C. G., Requena-Ibanez, J. A., San Antonio, R., Ishikawa, K., Watanabe, S., Picatoste, B., Flores, E., Garcia-Ropero, A., Sanz, J., Hajjar, R. J., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.01.056 · Cited by 651
Bedi, K. C., Snyder, N. W., Brandimarto, J., Aziz, M., Mesaros, C., Worth, A. J., Wang, L. L., Javaheri, A., Blair, I. A., Margulies, K. B., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.017545 · Cited by 650
Vallon, V., & Thomson, S. C. (2017) · Diabetologia · doi:10.1007/s00125-016-4157-3 · Cited by 635
Gene expression of the cardiac Na(+)-Ca2+ exchanger in end-stage human heart failure.
Studer, R., Reinecke, H., Bilger, J., Eschenhagen, T., Böhm, M., Hasenfuss, G., Just, H., Holtz, J., & Drexler, H. (1994) · Circulation Research · doi:10.1161/01.res.75.3.443 · Cited by 633
Gerich, J. E. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02894.x · Cited by 633
Active sugar transport in health and disease
Wright, E. M., Hirayama, B. A., & Loo, D. F. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01746.x · Cited by 627 · cited 1×
“It reabsorbs about 10% of filtered glucose with a glucose to sodium coupling ratio of 1:2 [65].”
BackgroundBasile, D. P., Donohoe, D., Roethe, K., & Osborn, J. L. (2001) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.2001.281.5.f887 · Cited by 619
Hemodynamically mediated glomerular injury and the progressive nature of kidney disease
Brenner, P. D. B. M. (1983) · Kidney International · doi:10.1038/ki.1983.72 · Cited by 614
Uthman, L., Baartscheer, A., Bleijlevens, B., Schumacher, C. A., Fiolet, J. W. T., Koeman, A., Jancev, M., Hollmann, M. W., Weber, N. C., Coronel, R., et al. (2018) · Diabetologia · doi:10.1007/s00125-017-4509-7 · Cited by 610
Franssen, C., Chen, S., Unger, A., Korkmaz, H. I., De Keulenaer, G. W., Tschöpe, C., Leite-Moreira, A. F., Musters, R., Niessen, H. W. M., Linke, W. A., et al. (2016) · JACC: Heart Failure · doi:10.1016/j.jchf.2015.10.007 · Cited by 597
Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors
DeFronzo, R. A., Reeves, W. B., & Awad, A. S. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00393-8 · Cited by 589
Li, C., Zhang, J., Xue, M., Li, X., Han, F., Liu, X., Xu, L., Lu, Y., Cheng, Y., Li, T., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0816-2 · Cited by 580
FRANCIS, G. S., SIEGEL, R. M., GOLDSMITH, S. R., OLIVARI, M. T., LEVINE, T. B., & COHN, J. N. (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-103-1-1 · Cited by 579
Verma, S., Mazer, C. D., Yan, A. T., Mason, T., Garg, V., Teoh, H., Zuo, F., Quan, A., Farkouh, M. E., Fitchett, D. H., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.042375 · Cited by 572
Mudaliar, S., Alloju, S., & Henry, R. R. (2016) · Diabetes Care · doi:10.2337/dc16-0542 · Cited by 571
Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
DeFronzo, R. A., Norton, L., & Abdul-Ghani, M. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.170 · Cited by 553
Zhou, H., Wang, S., Zhu, P., Hu, S., Chen, Y., & Ren, J. (2018) · Redox Biology · doi:10.1016/j.redox.2017.12.019 · Cited by 550
The Role of Autophagy in the Heart
Sciarretta, S., Maejima, Y., Zablocki, D., & Sadoshima, J. (2018) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021317-121427 · Cited by 547
Catabolic Defect of Branched-Chain Amino Acids Promotes Heart Failure
Sun, H., Olson, K. C., Gao, C., Prosdocimo, D. A., Zhou, M., Wang, Z., Jeyaraj, D., Youn, J.-Y., Ren, S., Liu, Y., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.020226 · Cited by 538
Kim, S. R., Lee, S.-G., Kim, S. H., Kim, J. H., Choi, E., Cho, W., Rim, J. H., Hwang, I., Lee, C. J., Lee, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15983-6 · Cited by 536
Nielsen, R., Møller, N., Gormsen, L. C., Tolbod, L. P., Hansson, N. H., Sorensen, J., Harms, H. J., Frøkiær, J., Eiskjaer, H., Jespersen, N. R., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.036459 · Cited by 518
Chilton, R., Tikkanen, I., Cannon, C. P., Crowe, S., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12572 · Cited by 507
Mitochondrial Fusion is Essential for Organelle Function and Cardiac Homeostasis
Chen, Y., Liu, Y., & Dorn, G. W. (2011) · Circulation Research · doi:10.1161/circresaha.111.258723 · Cited by 505
Lee, T.-M., Chang, N.-C., & Lin, S.-Z. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.01.035 · Cited by 504
Hallow, K. M., Helmlinger, G., Greasley, P. J., McMurray, J. J. V., & Boulton, D. W. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13126 · Cited by 499
Autophagy in kidney homeostasis and disease
Tang, C., Livingston, M. J., Liu, Z., & Dong, Z. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0309-2 · Cited by 496
Vallon, V., Gerasimova, M., Rose, M. A., Masuda, T., Satriano, J., Mayoux, E., Koepsell, H., Thomson, S. C., & Rieg, T. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00520.2013 · Cited by 483
The glucose transporter families SGLT and GLUT: molecular basis of normal and aberrant function
Scheepers, A., Joost, H., & Schurmann, A. (2004) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607104028005364 · Cited by 476 · cited 1×
“They show a high affinity and a high capacity to move glucose across the luminal membrane actively, and this active transport occurs against the concentration gradient [54,55].”
BackgroundHeerspink, H. J. L., Perco, P., Mulder, S., Leierer, J., Hansen, M. K., Heinzel, A., & Mayer, G. (2019) · Diabetologia · doi:10.1007/s00125-019-4859-4 · Cited by 457
Soluble Uric Acid Activates the NLRP3 Inflammasome
Braga, T. T., Forni, M. F., Correa-Costa, M., Ramos, R. N., Barbuto, J. A., Branco, P., Castoldi, A., Hiyane, M. I., Davanso, M. R., Latz, E., et al. (2017) · Scientific Reports · doi:10.1038/srep39884 · Cited by 440
Nassif, M. E., Windsor, S. L., Tang, F., Khariton, Y., Husain, M., Inzucchi, S. E., McGuire, D. K., Pitt, B., Scirica, B. M., Austin, B., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.042929 · Cited by 424
Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects
Griffin, M., Rao, V. S., Ivey-Miranda, J., Fleming, J., Mahoney, D., Maulion, C., Suda, N., Siwakoti, K., Ahmad, T., Jacoby, D., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.045691 · Cited by 414
Glomerular cell number in normal subjects and in type 1 diabetic patients
Steffes, M. W., Schmidt, D., Mccrery, R., & Basgen, J. M. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00725.x · Cited by 408
Basile, D. P., Donohoe, D., Roethe, K., & Osborn, J. L. (2001) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00050.2001 · Cited by 404
Overweight, Obesity, and the Development of Stage 3 CKD: The Framingham Heart Study
Foster, M. C., Hwang, S.-J., Larson, M. G., Lichtman, J. H., Parikh, N. I., Vasan, R. S., Levy, D., & Fox, C. S. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.03.003 · Cited by 403
Frías, J. P., Guja, C., Hardy, E., Ahmed, A., Dong, F., Öhman, P., & Jabbour, S. A. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30267-4 · Cited by 398
Mitochondrial dynamics: regulatory mechanisms and emerging role in renal pathophysiology
Zhan, M., Brooks, C., Liu, F., Sun, L., & Dong, Z. (2013) · Kidney International · doi:10.1038/ki.2012.441 · Cited by 397
The proximal tubule in the pathophysiology of the diabetic kidney
Vallon, V. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00809.2010 · Cited by 395
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
Heerspink, H. J. L., Kosiborod, M., Inzucchi, S. E., & Cherney, D. Z. I. (2018) · Kidney International · doi:10.1016/j.kint.2017.12.027 · Cited by 393
Empagliflozin Increases Cardiac Energy Production in Diabetes
Verma, S., Rawat, S., Ho, K. L., Wagg, C. S., Zhang, L., Teoh, H., Dyck, J. E., Uddin, G. M., Oudit, G. Y., Mayoux, E., et al. (2018) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.07.006 · Cited by 386
Cherney, D. Z. I., Zinman, B., Inzucchi, S. E., Koitka-Weber, A., Mattheus, M., von Eynatten, M., & Wanner, C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30182-1 · Cited by 383
Vallon, V., & Thomson, S. C. (2012) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020911-153333 · Cited by 376
Solini, A., Giannini, L., Seghieri, M., Vitolo, E., Taddei, S., Ghiadoni, L., & Bruno, R. M. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0621-8 · Cited by 373
Mazer, C. D., Hare, G. M. T., Connelly, P. W., Gilbert, R. E., Shehata, N., Quan, A., Teoh, H., Leiter, L. A., Zinman, B., Jüni, P., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044235 · Cited by 371
Vallon, V., Rose, M., Gerasimova, M., Satriano, J., Platt, K. A., Koepsell, H., Cunard, R., Sharma, K., Thomson, S. C., & Rieg, T. (2013) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00409.2012 · Cited by 370
Ye, Y., Bajaj, M., Yang, H.-C., Perez-Polo, J. R., & Birnbaum, Y. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6725-2 · Cited by 368
Ueda, P., Svanström, H., Melbye, M., Eliasson, B., Svensson, A.-M., Franzén, S., Gudbjörnsdottir, S., Hveem, K., Jonasson, C., & Pasternak, B. (2018) · BMJ · doi:10.1136/bmj.k4365 · Cited by 367
van Bommel, E. J. M., Muskiet, M. H. A., van Baar, M. J. B., Tonneijck, L., Smits, M. M., Emanuel, A. L., Bozovic, A., Danser, A. H. J., Geurts, F., Hoorn, E. J., et al. (2020) · Kidney International · doi:10.1016/j.kint.2019.09.013 · Cited by 363
Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
Ferrannini, G., Hach, T., Crowe, S., Sanghvi, A., Hall, K. D., & Ferrannini, E. (2015) · Diabetes Care · doi:10.2337/dc15-0355 · Cited by 359
Goldenberg, R. M., Berard, L. D., Cheng, A. Y. Y., Gilbert, J. D., Verma, S., Woo, V. C., & Yale, J.-F. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.11.002 · Cited by 354
Packer, M., Butler, J., Zannad, F., Filippatos, G., Ferreira, J. P., Pocock, S. J., Carson, P., Anand, I., Doehner, W., Haass, M., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.056824 · Cited by 354
The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure
Thomas, M. C., & Cherney, D. Z. I. (2018) · Diabetologia · doi:10.1007/s00125-018-4669-0 · Cited by 348
Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2
Ghezzi, C., Loo, D. D. F., & Wright, E. M. (2018) · Diabetologia · doi:10.1007/s00125-018-4656-5 · Cited by 348
11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s011 · Cited by 344
Terami, N., Ogawa, D., Tachibana, H., Hatanaka, T., Wada, J., Nakatsuka, A., Eguchi, J., Horiguchi, C. S., Nishii, N., Yamada, H., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100777 · Cited by 341
Malonyl-CoA: the regulator of fatty acid synthesis and oxidation
Foster, D. W. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63967 · Cited by 336
Zhao, Y., Xu, L., Tian, D., Xia, P., Zheng, H., Wang, L., & Chen, L. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13101 · Cited by 333
Hypoxia-inducible factors in the kidney
Haase, V. H. (2006) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00071.2006 · Cited by 332
SGLT inhibitors in management of diabetes
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70050-0 · Cited by 332
Kolijn, D., Pabel, S., Tian, Y., Lódi, M., Herwig, M., Carrizzo, A., Zhazykbayeva, S., Kovács, Á., Fülöp, G. Á., Falcão-Pires, I., et al. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvaa123 · Cited by 323
Heymans, S., Hirsch, E., Anker, S. D., Aukrust, P., Balligand, J.-L., Cohen-Tervaert, J. W., Drexler, H., Filippatos, G., Felix, S. B., Gullestad, L., et al. (2009) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfn043 · Cited by 323
Kohlhaas, M., Liu, T., Knopp, A., Zeller, T., Ong, M. F., Böhm, M., O'Rourke, B., & Maack, C. (2010) · Circulation · doi:10.1161/circulationaha.109.914911 · Cited by 322
Thomson, S. C., Rieg, T., Miracle, C., Mansoury, H., Whaley, J., Vallon, V., & Singh, P. (2012) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00357.2011 · Cited by 315
FGF21 as Modulator of Metabolism in Health and Disease
Tezze, C., Romanello, V., & Sandri, M. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00419 · Cited by 315
Tahara, A., Kurosaki, E., Yokono, M., Yamajuku, D., Kihara, R., Hayashizaki, Y., Takasu, T., Imamura, M., Li, Q., Tomiyama, H., et al. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.05.014 · Cited by 310
Uric Acid in Inflammation and the Pathogenesis of Atherosclerosis
Kimura, Y., Tsukui, D., & Kono, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212394 · Cited by 309
Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members
Chen, J., Williams, S., Ho, S., Loraine, H., Hagan, D., Whaley, J. M., & Feder, J. N. (2010) · Diabetes Therapy · doi:10.1007/s13300-010-0006-4 · Cited by 307
The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
Steven, S., Oelze, M., Hanf, A., Kröller-Schön, S., Kashani, F., Roohani, S., Welschof, P., Kopp, M., Gödtel-Armbrust, U., Xia, N., et al. (2017) · Redox Biology · doi:10.1016/j.redox.2017.06.009 · Cited by 298
SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study
Abdul-Ghani, M., Del Prato, S., Chilton, R., & DeFronzo, R. A. (2016) · Diabetes Care · doi:10.2337/dc16-0041 · Cited by 295
DeFronzo, R. A., Hompesch, M., Kasichayanula, S., Liu, X., Hong, Y., Pfister, M., Morrow, L. A., Leslie, B. R., Boulton, D. W., Ching, A., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0387 · Cited by 293
Oelze, M., Kröller-Schön, S., Welschof, P., Jansen, T., Hausding, M., Mikhed, Y., Stamm, P., Mader, M., Zinßius, E., Agdauletova, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112394 · Cited by 293
Glucagon-like peptide 1(GLP-1) in biology and pathology
Meier, J. J., & Nauck, M. A. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.538 · Cited by 288 · cited 1×
“The association with the GLP-1 receptor agonists (GLP-1RAs) could prevent the decrease in plasma insulin and the increase in plasma glucagon induced by gliflozins and obtain a greater decline in both circulating blood glucose and body weight [32].”
BackgroundCherney, D. Z. I., Dekkers, C. C. J., Barbour, S. J., Cattran, D., Abdul Gafor, A. H., Greasley, P. J., Laverman, G. D., Lim, S. K., Di Tanna, G. L., Reich, H. N., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30162-5 · Cited by 283
Kidokoro, K., Cherney, D. Z. I., Bozovic, A., Nagasu, H., Satoh, M., Kanda, E., Sasaki, T., & Kashihara, N. (2019) · Circulation · doi:10.1161/circulationaha.118.037418 · Cited by 283
Hypoxia as a key player in the AKI-to-CKD transition
Tanaka, S., Tanaka, T., & Nangaku, M. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00425.2014 · Cited by 280
Sano, M., & Goto, S. (2019) · Circulation · doi:10.1161/circulationaha.118.038881 · Cited by 278
Severity and Frequency of Proximal Tubule Injury Determines Renal Prognosis
Takaori, K., Nakamura, J., Yamamoto, S., Nakata, H., Sato, Y., Takase, M., Nameta, M., Yamamoto, T., Economides, A. N., Kohno, K., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015060647 · Cited by 277
Yancy, C. W., Januzzi, J. L., Allen, L. A., Butler, J., Davis, L. L., Fonarow, G. C., Ibrahim, N. E., Jessup, M., Lindenfeld, J., Maddox, T. M., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.025 · Cited by 275
Sa-nguanmoo, P., Tanajak, P., Kerdphoo, S., Jaiwongkam, T., Pratchayasakul, W., Chattipakorn, N., & Chattipakorn, S. C. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.08.005 · Cited by 274
Garvey, W. T., Van Gaal, L., Leiter, L. A., Vijapurkar, U., List, J., Cuddihy, R., Ren, J., & Davies, M. J. (2018) · Metabolism · doi:10.1016/j.metabol.2018.02.002 · Cited by 261
Byrne, N. J., Matsumura, N., Maayah, Z. H., Ferdaoussi, M., Takahara, S., Darwesh, A. M., Levasseur, J. L., Jahng, J. W. S., Vos, D., Parajuli, N., et al. (2020) · Circulation: Heart Failure · doi:10.1161/circheartfailure.119.006277 · Cited by 257
Sano, M., Takei, M., Shiraishi, Y., & Suzuki, Y. (2016) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2760w · Cited by 252
Sha, S., Polidori, D., Heise, T., Natarajan, J., Farrell, K., Wang, S. ‐., Sica, D., Rothenberg, P., & Plum‐Mörschel, L. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12322 · Cited by 249
Shigiyama, F., Kumashiro, N., Miyagi, M., Ikehara, K., Kanda, E., Uchino, H., & Hirose, T. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0564-0 · Cited by 249
Lee, D. M., Battson, M. L., Jarrell, D. K., Hou, S., Ecton, K. E., Weir, T. L., & Gentile, C. L. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0708-x · Cited by 246
Zambrowicz, B., Freiman, J., Brown, P. M., Frazier, K. S., Turnage, A., Bronner, J., Ruff, D., Shadoan, M., Banks, P., Mseeh, F., et al. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.58 · Cited by 243
O'Neill, J., Fasching, A., Pihl, L., Patinha, D., Franzén, S., & Palm, F. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00689.2014 · Cited by 232
Juxtaglomerular cell complex in the regulation of renal salt excretion
Schnermann, J. (1998) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1998.274.2.r263 · Cited by 231
SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms
Osataphan, S., Macchi, C., Singhal, G., Chimene-Weiss, J., Sales, V., Kozuka, C., Dreyfuss, J. M., Pan, H., Tangcharoenpaisan, Y., Morningstar, J., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.123130 · Cited by 228
Hamdani, N., Bishu, K. G., von Frieling-Salewsky, M., Redfield, M. M., & Linke, W. A. (2013) · Cardiovascular Research · doi:10.1093/cvr/cvs353 · Cited by 227
Mustroph, J., Wagemann, O., Lücht, C. M., Trum, M., Hammer, K. P., Sag, C. M., Lebek, S., Tarnowski, D., Reinders, J., Perbellini, F., et al. (2018) · ESC Heart Failure · doi:10.1002/ehf2.12336 · Cited by 225
Empagliflozin directly improves diastolic function in human heart failure
Pabel, S., Wagner, S., Bollenberg, H., Bengel, P., Kovács, Á., Schach, C., Tirilomis, P., Mustroph, J., Renner, A., Gummert, J., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1328 · Cited by 224
SGLT2 Inhibition in the Diabetic Kidney—From Mechanisms to Clinical Outcome
van Bommel, E. J. M., Muskiet, M. H. A., Tonneijck, L., Kramer, M. H. H., Nieuwdorp, M., & van Raalte, D. H. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06080616 · Cited by 222
Brown, E., Wilding, J. P. H., Barber, T. M., Alam, U., & Cuthbertson, D. J. (2019) · Obesity Reviews · doi:10.1111/obr.12841 · Cited by 222
SGLT2 Deletion Improves Glucose Homeostasis and Preserves Pancreatic β-Cell Function
Jurczak, M. J., Lee, H.-Y., Birkenfeld, A. L., Jornayvaz, F. R., Frederick, D. W., Pongratz, R. L., Zhao, X., Moeckel, G. W., Samuel, V. T., Whaley, J. M., et al. (2011) · Diabetes · doi:10.2337/db10-1328 · Cited by 219
Patel, V. B., Shah, S., Verma, S., & Oudit, G. Y. (2017) · Heart Failure Reviews · doi:10.1007/s10741-017-9644-1 · Cited by 218
Abraham, W. T., Lindenfeld, J., Ponikowski, P., Agostoni, P., Butler, J., Desai, A. S., Filippatos, G., Gniot, J., Fu, M., Gullestad, L., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa943 · Cited by 217
Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes
Daniele, G., Xiong, J., Solis-Herrera, C., Merovci, A., Eldor, R., Tripathy, D., DeFronzo, R. A., Norton, L., & Abdul-Ghani, M. (2016) · Diabetes Care · doi:10.2337/dc15-2688 · Cited by 213
Wanner, C., Heerspink, H. J. L., Zinman, B., Inzucchi, S. E., Koitka-Weber, A., Mattheus, M., Hantel, S., Woerle, H.-J., Broedl, U. C., von Eynatten, M., et al. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018010103 · Cited by 209
Pollock, C., Stefánsson, B., Reyner, D., Rossing, P., Sjöström, C. D., Wheeler, D. C., Langkilde, A. M., & Heerspink, H. J. L. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30086-5 · Cited by 205
Lee, H.-C., Shiou, Y.-L., Jhuo, S.-J., Chang, C.-Y., Liu, P.-L., Jhuang, W.-J., Dai, Z.-K., Chen, W.-Y., Chen, Y.-F., & Lee, A.-S. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0849-6 · Cited by 204
Philippaert, K., Kalyaanamoorthy, S., Fatehi, M., Long, W., Soni, S., Byrne, N. J., Barr, A., Singh, J., Wong, J., Palechuk, T., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.053350 · Cited by 204
Baartscheer, A. (2003) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00809-x · Cited by 203
Zheng, R., Zhou, D., & Zhu, Y. (2016) · Journal of Epidemiology and Community Health · doi:10.1136/jech-2015-206948 · Cited by 203
Hesp, A. C., Schaub, J. A., Prasad, P. V., Vallon, V., Laverman, G. D., Bjornstad, P., & van Raalte, D. H. (2020) · Kidney International · doi:10.1016/j.kint.2020.02.041 · Cited by 202
Juni, R. P., Kuster, D. W. D., Goebel, M., Helmes, M., Musters, R. J. P., van der Velden, J., Koolwijk, P., Paulus, W. J., & van Hinsbergh, V. W. M. (2019) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2019.04.003 · Cited by 202
Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis
Ghanim, H., Abuaysheh, S., Hejna, J., Green, K., Batra, M., Makdissi, A., Chaudhuri, A., & Dandona, P. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa057 · Cited by 197
Hayashi, T., Fukui, T., Nakanishi, N., Yamamoto, S., Tomoyasu, M., Osamura, A., Ohara, M., Yamamoto, T., Ito, Y., & Hirano, T. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0491-5 · Cited by 196
Fioretto, P., Del Prato, S., Buse, J. B., Goldenberg, R., Giorgino, F., Reyner, D., Langkilde, A. M., Sjöström, C. D., Sartipy, P., & On Behalf of the DERIVE Study Investigators (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13413 · Cited by 195
Empagliflozin protects heart from inflammation and energy depletion via AMPK activation
Koyani, C. N., Plastira, I., Sourij, H., Hallström, S., Schmidt, A., Rainer, P. P., Bugger, H., Frank, S., Malle, E., & von Lewinski, D. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104870 · Cited by 194
Sun, X., Han, F., Lu, Q., Li, X., Ren, D., Zhang, J., Han, Y., Xiang, Y. K., & Li, J. (2020) · Diabetes · doi:10.2337/db19-0991 · Cited by 193
Weber, T., Wassertheurer, S., Rammer, M., Haiden, A., Hametner, B., & Eber, B. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.194571 · Cited by 192
Freitas, H. S., Anhê, G. F., Melo, K. F. S., Okamoto, M. M., Oliveira-Souza, M., Bordin, S., & Machado, U. F. (2008) · Endocrinology · doi:10.1210/en.2007-1088 · Cited by 192
Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy
Lee, Y. H., Kim, S. H., Kang, J. M., Heo, J. H., Kim, D.-J., Park, S. H., Sung, M., Kim, J., Oh, J., Yang, D. H., et al. (2019) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00565.2018 · Cited by 189
Jiang, K., Xu, Y., Wang, D., Chen, F., Tu, Z., Qian, J., Xu, S., Xu, Y., Hwa, J., Li, J., et al. (2022) · Protein & Cell · doi:10.1007/s13238-020-00809-4 · Cited by 187
The Effects of SGLT2 Inhibitors on Lipid Metabolism
Szekeres, Z., Toth, K., & Szabados, E. (2021) · Metabolites · doi:10.3390/metabo11020087 · Cited by 187
SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1
Novikov, A., Fu, Y., Huang, W., Freeman, B., Patel, R., van Ginkel, C., Koepsell, H., Busslinger, M., Onishi, A., Nespoux, J., et al. (2019) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00462.2018 · Cited by 186
Dapagliflozin Lowers Plasma Glucose Concentration and Improves β-Cell Function
Merovci, A., Mari, A., Solis, C., Xiong, J., Daniele, G., Chavez-Velazquez, A., Tripathy, D., Urban McCarthy, S., Abdul-Ghani, M., & DeFronzo, R. A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3472 · Cited by 186
Pessoa, T. D., Campos, L. C. G., Carraro-Lacroix, L., Girardi, A. C. C., & Malnic, G. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013060588 · Cited by 184 · cited 1×
“This result can explain the significant SGLT2-I-induced natriuresis as demonstrated in proximal tubules of non-diabetic rats perfused with phlorizin [64].”
BackgroundSGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial
Karg, M. V., Bosch, A., Kannenkeril, D., Striepe, K., Ott, C., Schneider, M. P., Boemke-Zelch, F., Linz, P., Nagel, A. M., Titze, J., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0654-z · Cited by 182
Ferrannini, E., Baldi, S., Frascerra, S., Astiarraga, B., Barsotti, E., Clerico, A., & Muscelli, E. (2017) · Diabetes Care · doi:10.2337/dc16-2724 · Cited by 181
Regulatory mechanisms of Na + /glucose cotransporters in renal proximal tubule cells
Lee, Y. J., Lee, Y. J., & Han, H. J. (2007) · Kidney International · doi:10.1038/sj.ki.5002383 · Cited by 179
Aroor, A. R., Das, N. A., Carpenter, A. J., Habibi, J., Jia, G., Ramirez-Perez, F. I., Martinez-Lemus, L., Manrique-Acevedo, C. M., Hayden, M. R., Duta, C., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0750-8 · Cited by 179
Durak, A., Olgar, Y., Degirmenci, S., Akkus, E., Tuncay, E., & Turan, B. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0790-0 · Cited by 179
SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy
Cassis, P., Locatelli, M., Cerullo, D., Corna, D., Buelli, S., Zanchi, C., Villa, S., Morigi, M., Remuzzi, G., Benigni, A., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.98720 · Cited by 173
Adingupu, D. D., Göpel, S. O., Grönros, J., Behrendt, M., Sotak, M., Miliotis, T., Dahlqvist, U., Gan, L.-M., & Jönsson-Rylander, A.-C. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0820-6 · Cited by 172
Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Pocock, S. J., Sattar, N., Brueckmann, M., Jamal, W., Cotton, D., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.01.033 · Cited by 172
Fukao, T., Song, X.-Q., Mitchell, G. A., Yamaguchi, S., Sukegawa, K., Or, T., & Kondo, N. (1997) · Pediatric Research · doi:10.1203/00006450-199710000-00013 · Cited by 171
Adverse effects and safety of SGLT-2 inhibitors
Halimi, S., & Vergès, B. L. (2014) · Diabetes & Metabolism · doi:10.1016/s1262-3636(14)72693-x · Cited by 170
Kusaka, H., Koibuchi, N., Hasegawa, Y., Ogawa, H., & Kim‐Mitsuyama, S. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0473-7 · Cited by 169
Striepe, K., Jumar, A., Ott, C., Karg, M. V., Schneider, M. P., Kannenkeril, D., & Schmieder, R. E. (2017) · Circulation · doi:10.1161/circulationaha.117.029529 · Cited by 169
Mizuno, M., Kuno, A., Yano, T., Miki, T., Oshima, H., Sato, T., Nakata, K., Kimura, Y., Tanno, M., & Miura, T. (2018) · Physiological Reports · doi:10.14814/phy2.13741 · Cited by 169
Sodium—Glucose cotransporter inhibitors and oxidative stress: An update
Yaribeygi, H., Atkin, S. L., Butler, A. E., & Sahebkar, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.26760 · Cited by 167
Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors
Wilcox, C. S. (2020) · Hypertension · doi:10.1161/hypertensionaha.119.11684 · Cited by 167
Iannantuoni, F., M. de Marañon, A., Diaz-Morales, N., Falcon, R., Bañuls, C., Abad-Jimenez, Z., Victor, V. M., Hernandez-Mijares, A., & Rovira-Llopis, S. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111814 · Cited by 166
Kang, S., Verma, S., Hassanabad, A. F., Teng, G., Belke, D. D., Dundas, J. A., Guzzardi, D. G., Svystonyuk, D. A., Pattar, S. S., Park, D. S. J., et al. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2019.08.033 · Cited by 166
Poulsen, S. B., Fenton, R. A., & Rieg, T. (2015) · Current Opinion in Nephrology and Hypertension · doi:10.1097/mnh.0000000000000152 · Cited by 164
Butler, J., Hamo, C. E., Filippatos, G., Pocock, S. J., Bernstein, R. A., Brueckmann, M., Cheung, A. K., George, J. T., Green, J. B., Januzzi, J. L., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.933 · Cited by 164
Chang, H.-Y., Singh, S., Mansour, O., Baksh, S., & Alexander, G. C. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.3034 · Cited by 163
Aragón-Herrera, A., Feijóo-Bandín, S., Otero Santiago, M., Barral, L., Campos-Toimil, M., Gil-Longo, J., Costa Pereira, T. M., García-Caballero, T., Rodríguez-Segade, S., Rodríguez, J., et al. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113677 · Cited by 163
Umino, H., Hasegawa, K., Minakuchi, H., Muraoka, H., Kawaguchi, T., Kanda, T., Tokuyama, H., Wakino, S., & Itoh, H. (2018) · Scientific Reports · doi:10.1038/s41598-018-25054-y · Cited by 162
The Importance of Telemedicine during COVID-19 Pandemic: A Focus on Diabetic Retinopathy
Galiero, R., Pafundi, P. C., Nevola, R., Rinaldi, L., Acierno, C., Caturano, A., Salvatore, T., Adinolfi, L. E., Costagliola, C., & Sasso, F. C. (2020) · Journal of Diabetes Research · doi:10.1155/2020/9036847 · Cited by 162
Self-citationXu, C., Wang, W., Zhong, J., Lei, F., Xu, N., Zhang, Y., & Xie, W. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.03.013 · Cited by 161
Cardiac effects of SGLT2 inhibitors: the sodium hypothesis
Bertero, E., Prates Roma, L., Ameri, P., & Maack, C. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvx149 · Cited by 160
Škrtić, M., Yang, G. K., Perkins, B. A., Soleymanlou, N., Lytvyn, Y., von Eynatten, M., Woerle, H. J., Johansen, O. E., Broedl, U. C., Hach, T., et al. (2014) · Diabetologia · doi:10.1007/s00125-014-3396-4 · Cited by 159
Yaribeygi, H., Butler, A. E., Atkin, S. L., Katsiki, N., & Sahebkar, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26851 · Cited by 159
Improved glycemic control in mice lacking Sglt1 and Sglt2
Powell, D. R., DaCosta, C. M., Gay, J., Ding, Z.-M., Smith, M., Greer, J., Doree, D., Jeter-Jones, S., Mseeh, F., Rodriguez, L. A., et al. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00439.2012 · Cited by 158
Verma, S., McMurray, J. J. V., & Cherney, D. Z. I. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.1891 · Cited by 158
Kappel, B. A., Lehrke, M., Schütt, K. S., Artati, A., Adamski, J., Lebherz, C., & Marx, N. (2017) · Circulation · doi:10.1161/circulationaha.117.029166 · Cited by 157
Škrtić, M., & Cherney, D. Z. I. (2014) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000084 · Cited by 156
Anker, S. D., Butler, J., Filippatos, G. S., Khan, M. S., Ferreira, J. P., Bocchi, E. A., Böhm, M., Rocca, H. B., Choi, D., Chopra, V., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.2064 · Cited by 156
Liu, Z., Ma, X., Ilyas, I., Zheng, X., Luo, S., Little, P. J., Kamato, D., Sahebkar, A., Wu, W., Weng, J., et al. (2021) · Theranostics · doi:10.7150/thno.54498 · Cited by 155
THE ACTION OF PHLORIZIN ON THE EXCRETION OF GLUCOSE, XYLOSE, SUCROSE, CREATININE AND UREA BY MAN
Chasis, H., Jolliffe, N., & Smith, H. W. (1933) · Journal of Clinical Investigation · doi:10.1172/jci100559 · Cited by 152
SGLT2 Inhibitors and Their Mode of Action in Heart Failure—Has the Mystery Been Unravelled?
Pabel, S., Hamdani, N., Luedde, M., & Sossalla, S. T. (2021) · Current Heart Failure Reports · doi:10.1007/s11897-021-00529-8 · Cited by 152
Obata, A., Kubota, N., Kubota, T., Iwamoto, M., Satō, H., Sakurai, Y., Takamoto, I., Katsuyama, H., Suzuki, Y., Fukazawa, M., et al. (2015) · Endocrinology · doi:10.1210/en.2015-1588 · Cited by 143
Effects of SGLT2 inhibitors and GLP-1 receptor agonists on renin-angiotensin-aldosterone system
Puglisi, S., Rossini, A., Poli, R., Dughera, F., Pia, A., Terzolo, M., & Reimondo, G. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.738848 · Cited by 143
Pfeifer, M. A., Townsend, R. R., Davies, M. J., Vijapurkar, U., & Ren, J. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0511-0 · Cited by 142
Cited by
Guo, W., Song, Y., Sun, Y., Du, H., Cai, Y., You, Q., Fu, H., & Shao, L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1071465 · Cited by 335
Salvatore, T., Galiero, R., Caturano, A., Vetrano, E., Loffredo, G., Rinaldi, L., Catalini, C., Gjeloshi, K., Albanese, G., Di Martino, A., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10092274 · Cited by 98
Self-citation
Metadata
- Authors
- Salvatore, T., Galiero, R., Caturano, A., Rinaldi, L., Di Martino, A., Albanese, G., Di Salvo, J., Epifani, R., Marfella, R., Docimo, G., Lettieri, M., Sardu, C., & Sasso, F. C.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-03-26
- Volume
- 23
- Issue
- 7
- Pages
- 3651
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W4220742762
- Cited by
- 256
- References
- 346
- FWCI
- 31.47
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.